Idexx Laboratories Inc. (NASDAQ:IDXX) shares hit a new 52-week high on Tuesday . The company traded as high as $111.14 and last traded at $111.10, with a volume of 208,128 shares changing hands. The stock had previously closed at $108.62.

A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of Idexx Laboratories from a “hold” rating to a “buy” rating and set a $106.00 price target on the stock in a research note on Monday, July 25th. Stifel Nicolaus reiterated a “buy” rating and issued a $120.00 price objective (up from $92.00) on shares of Idexx Laboratories in a report on Wednesday, August 3rd. Canaccord Genuity reiterated a “buy” rating and issued a $85.00 price objective (up from $80.00) on shares of Idexx Laboratories in a report on Tuesday, April 19th. Northcoast Research upgraded shares of Idexx Laboratories from a “sell” rating to a “neutral” rating in a report on Wednesday, August 3rd. Finally, Credit Suisse Group AG lifted their price objective on shares of Idexx Laboratories from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Wednesday, April 13th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $99.80.

The stock has a market cap of $9.95 billion and a price-to-earnings ratio of 50.36. The firm has a 50-day moving average price of $94.76 and a 200 day moving average price of $83.37.

Idexx Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.12. The business had revenue of $467 million for the quarter, compared to the consensus estimate of $444.83 million. Idexx Laboratories’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.60 earnings per share. Analysts anticipate that Idexx Laboratories Inc. will post $2.35 EPS for the current year.

In related news, Chairman Jonathan W. Ayers sold 60,000 shares of the stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $107.69, for a total value of $6,461,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William T. End sold 5,000 shares of the stock in a transaction on Friday, August 5th. The stock was sold at an average price of $108.50, for a total value of $542,500.00. Following the completion of the transaction, the director now owns 53,564 shares in the company, valued at $5,811,694. The disclosure for this sale can be found here.

A number of large investors recently added to or reduced their stakes in IDXX. Advisors Asset Management Inc. raised its stake in Idexx Laboratories by 2.9% in the fourth quarter. Advisors Asset Management Inc. now owns 17,027 shares of the company’s stock worth $1,242,000 after buying an additional 487 shares during the last quarter. US Bancorp DE raised its stake in Idexx Laboratories by 7.2% in the fourth quarter. US Bancorp DE now owns 39,115 shares of the company’s stock worth $2,853,000 after buying an additional 2,612 shares during the last quarter. Principal Financial Group Inc. raised its stake in Idexx Laboratories by 1.8% in the fourth quarter. Principal Financial Group Inc. now owns 296,034 shares of the company’s stock worth $21,587,000 after buying an additional 5,318 shares during the last quarter. BlackRock Advisors LLC raised its stake in Idexx Laboratories by 27.6% in the fourth quarter. BlackRock Advisors LLC now owns 173,557 shares of the company’s stock worth $12,656,000 after buying an additional 37,536 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Idexx Laboratories by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,331,556 shares of the company’s stock worth $461,697,000 after buying an additional 60,129 shares during the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.